Literature DB >> 20084472

Metastatic breast cancer mimicking hepatocellular carcinoma: differences in noninvasive guidelines.

Anna H Bartram1, John Lee Villano, Dean M Ferrera.   

Abstract

Hepatocellular carcinoma (HCC), unlike most solid tumors, can be diagnosed noninvasively. We present a case that highlights an important clinical difference between two established guidelines: National Cancer Comprehensive Network (NCCN) and Barcelona-2000 EASL Conference (European Association for the Study of the Liver). Our patient had a large liver mass extending into the right atrium with elevation of the alpha-fetoprotein to 1,130 ng/mL. The radiographic and laboratory evidence is sufficient using NCCN guidelines to initiate palliative treatment for HCC. The Barcelona-2000 EASL Conference guideline for noninvasive diagnosis is restricted to cirrhotic patients. Our patient did not have a history of chronic liver disease or active hepatitis, and a biopsy was performed that demonstrated breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20084472     DOI: 10.1007/s12029-009-9129-0

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  8 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.

Authors:  Nina Bijker; Philip Meijnen; Johannes L Peterse; Jan Bogaerts; Irène Van Hoorebeeck; Jean-Pierre Julien; Massimiliano Gennaro; Philippe Rouanet; Antoine Avril; Ian S Fentiman; Harry Bartelink; Emiel J Th Rutgers
Journal:  J Clin Oncol       Date:  2006-06-26       Impact factor: 44.544

3.  Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study.

Authors:  Jessica A Davila; Robert O Morgan; Yasser Shaib; Katherine A McGlynn; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

4.  Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.

Authors:  T Kuukasjärvi; J Kononen; H Helin; K Holli; J Isola
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

5.  A comparative study of four serological tumor markers for the detection of breast cancer.

Authors:  Shawn R Clinton; Kevin L Beason; Sabrina Bryant; James T Johnson; Margaret Jackson; Cynthia Wilson; Kay Holifield; Charlton Vincent; Margot Hall
Journal:  Biomed Sci Instrum       Date:  2003

6.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

Review 7.  Hepatocellular carcinoma.

Authors:  Jorge A Marrero
Journal:  Curr Opin Gastroenterol       Date:  2006-05       Impact factor: 3.287

8.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.